Clinical trial of tolerance of HPA-23 in patients with acquired immune deficiency syndrome.

Abstract

An open-label, multicenter clinical trial assessed the tolerance of HPA-23 (ammonium-21-tungsto-9-antimoniate) in patients with acquired immune deficiency syndrome. Sixty-nine patients were sequentially assigned to receive 0.25, 0.5, 1.0, or 2.0 mg of HPA-23 per kg intravenously 5 days per week for 8 weeks. HPA-23 was fairly well tolerated at doses of 1.0 mg/kg or less; nearly 60% of patients given 2.0 mg/kg discontinued treatment. Twenty-six patients discontinued treatment because of adverse events or concurrent illness. HPA-23 produced dose-related decreases in platelet count and increases in serum glutamine oxalacetic transaminase. There were no changes in immune system function, as determined by total lymphocyte count, T4-cell count, T8-cell count, and T4/T8 ratio. The effects of HPA-23 seemed to be more closely related to the total dose than to the daily dose. No improvement in the clinical status of the patients was observed during the 8 weeks of treatment.

• Authors: B L Moskovitz
• Journal: Antimicrobial agents and chemotherapy (Antimicrob Agents Chemother) Vol. 32 Issue 9 Pg. 1300-3 (Sep 1988) ISSN: 0066-4804 [Print] United States
• PMID: 3058016 (Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article)

Chemical References

• Antiviral Agents
• Tungsten Compounds
• ammonium tungsten antimonate hydroxide oxide
• Antimony
• Aspartate Aminotransferases
• Tungsten

Topics

• Acquired Immunodeficiency Syndrome (blood, drug therapy)
• Adult
• Antimony (therapeutic use)
• Antiviral Agents (therapeutic use)
• Aspartate Aminotransferases (blood)
• Blood Cell Count (drug effects)
• Clinical Trials as Topic
• Drug Tolerance
• Humans
• Male
• Platelet Count (drug effects)
• T-Lymphocytes (drug effects)
• Tungsten (therapeutic use)
• Tungsten Compounds